# Reboxetine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/reboxetine

> The PDUFA target action date for reboxetine, sponsored by Axsome Therapeutics, Inc. (AXSM), is May 1, 2027, for cataplexy in narcolepsy. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the reboxetine PDUFA date?

The PDUFA target action date for reboxetine, sponsored by Axsome Therapeutics, Inc. (AXSM), is May 1, 2027, for cataplexy in narcolepsy. Status: scheduled. Press release filed with the SEC (EX-99): "AXS-12 for cataplexy in narcolepsy, PDUFA target action (May 1, 2027)" Last confirmed November 2, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/reboxetine)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-442628, https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-02. Cite: https://sec-api.dev/pdufa/reboxetine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | reboxetine |
| Codes | AXS-12 |
| Sponsor | Axsome Therapeutics, Inc. (AXSM) https://sec-api.dev/companies/axsm/catalysts |
| Indications | [cataplexy in narcolepsy](https://sec-api.dev/indications/cataplexy-in-narcolepsy), narcolepsy, [central nervous system](https://sec-api.dev/indications/central-nervous-system), cataplexy in patients with narcolepsy |
| Modality |  |
| FDA designations | breakthrough, orphan |

## Timeline

### Mar 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0000950170-24-124758): "In March 2024, we reported positive topline data from the Phase 3 trial of AXS-12 in narcolepsy, which we call the SYMPHONY study." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124758/axsm-20240930.htm

### Q4 2024: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "Topline results of ENCORE Phase 3 trial of AXS-12 in narcolepsy on track for 4Q 2024" https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "Enrollment in the ENCORE trial is complete, and the Company remains on track to report topline results from the trial in the fourth quarter of 2024." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm

### 2H 2025: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-02-18, last confirmed 2025-02-18.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "NDA submission anticipated in 2H 2025 Positive topline results of third Ph 3 trial of AXS-12 in narcolepsy announced" https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm

### Jan 2026: NDA/BLA submission

- Status: scheduled. Date confidence: month. Stage: 3. Indication: narcolepsy.
- First seen 2025-02-18, last confirmed 2025-12-31.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-337644): "Axsome anticipates completing the NDA submission in January 2026." https://www.sec.gov/Archives/edgar/data/1579428/000119312525337644/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261651): "Narcolepsy: Axsome plans to submit an NDA to the FDA for AXS-12 for the treatment of cataplexy in narcolepsy in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 4Q 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "Narcolepsy: Axsome plans to submit an NDA to the FDA for AXS-12 for the treatment of cataplexy in narcolepsy in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 2H 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "Rate Ratio* p=0.007 p=0.006 p=0.031 p=0.031 p=0.018 *Ratio of change in the AXS-12 group divided by the ratio of change in the placebo group SYMPHONY Primary endpoint: Change from baseline in weekly cataplexy attacks Statistically significant reductions in cataplexy frequency CONCERT p<0.001 p=0.002 Baseline Week 1 Week 2 4.0 0.0 -4.0 -8.0 -12.0 -16.0 -20.0 Change in Weekly Cataplexy Attacks Change in Weekly Cataplexy Attacks New Drug Application (NDA) submission anticipated 2H 2025 New Drug Application (NDA) submission anticipated 2H 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "Positive topline results of ENCORE Phase 3 trial of AXS-12 in narcolepsy announced; NDA submission anticipated in 2H 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "Based on the results from these studies, Axsome plans to submit an NDA for AXS-12 for the treatment of cataplexy in patients with narcolepsy to the FDA in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "NDA submission anticipated in 2H 2025 Positive topline results of third Ph 3 trial of AXS-12 in narcolepsy announced" https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "Rate Ratio* p=0.007 p=0.006 p=0.031 p=0.031 p=0.018 *Ratio of change in the AXS-12 group divided by the ratio of change in the placebo group SYMPHONY Primary endpoint: Change from baseline in weekly cataplexy attacks Statistically significant reductions in cataplexy frequency CONCERT p<0.001 p=0.002 Baseline Week 1 Week 2 4.0 0.0 -4.0 -8.0 -12.0 -16.0 -20.0 Change in Weekly Cataplexy Attacks Change in Weekly Cataplexy Attacks New Drug Application (NDA) submission anticipated 2H 2025 New Drug Application (NDA) submission anticipated 2H 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "The Company anticipates submitting an NDA to the FDA in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm

### July 15, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: cataplexy in narcolepsy.
- First seen 2026-07-15, last confirmed 2026-11-02.
- SEC Form 10-Q (accession 0001193125-26-443752): "In July 2026, the FDA accepted for filing our New Drug Application (NDA) for AXS-12 for the treatment of cataplexy in narcolepsy." https://www.sec.gov/Archives/edgar/data/1579428/000119312526443752/axsm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-443752): "Furthermore, we submitted an NDA for AXS-12 for the treatment of cataplexy in narcolepsy, which was accepted by the FDA in July 2026 with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526443752/axsm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-342360): "In July 2026, the FDA accepted for filing the Company's New Drug Application (NDA) for AXS-12 for the treatment of cataplexy in narcolepsy." https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-342360): "Furthermore, we submitted an NDA for AXS-12 for the treatment of cataplexy in narcolepsy, which was accepted by the FDA in July 2026 with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm
- SEC Form 8-K (accession 0001193125-26-304039): "On July 15, 2026, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy." https://www.sec.gov/Archives/edgar/data/1579428/000119312526304039/axsm-20260715.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-304039): "NEW YORK, July 15, 2026 (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy." https://www.sec.gov/Archives/edgar/data/1579428/000119312526304039/axsm-ex99_1.htm

### May 1, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: cataplexy in narcolepsy.
- First seen 2026-07-15, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-442628): "AXS-12 for cataplexy in narcolepsy, PDUFA target action (May 1, 2027)" https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341206): "NDA submission for AXS-12 for cataplexy in narcolepsy accepted by the FDA with PDUFA target action date of May 1, 2027" https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341206): "Narcolepsy: Axsome's NDA submission for AXS-12 for the treatment of cataplexy in narcolepsy was accepted by the FDA and assigned a PDUFA target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341206): "AXS-12 for narcolepsy, PDUFA target action (May 1, 2027)" https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341206): "Rate ratio* p=0.007 p=0.006 p=0.031 p=0.031 p=0.018 p<0.001 p=0.002 *Ratio of change in the AXS-12 group divided by the ratio of change in the placebo group (rate ratio of 1 = no difference) CONCERT SYMPHONY Rapid and robust reductions in cataplexy with AXS-12 treatment NDA for AXS-12 for cataplexy in narcolepsy accepted by the FDA with PDUFA target action date of May 1, 2027" https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_2.htm
- SEC Form 10-Q (accession 0001193125-26-443752): "Furthermore, we submitted an NDA for AXS-12 for the treatment of cataplexy in narcolepsy, which was accepted by the FDA in July 2026 with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526443752/axsm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-342360): "Furthermore, we submitted an NDA for AXS-12 for the treatment of cataplexy in narcolepsy, which was accepted by the FDA in July 2026 with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-442628): "The PDUFA target action date is May 1, 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-304039): "FDA sets PDUFA target action date of May 1, 2027" https://www.sec.gov/Archives/edgar/data/1579428/000119312526304039/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-304039): "The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526304039/axsm-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-443752): "The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526443752/axsm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-342360): "The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm

## Same indication

- [AUVELITY (dextromethorphan-bupropion)](https://sec-api.dev/pdufa/dextromethorphan-bupropion) (AXSM)
- [SYMBRAVO® (meloxicam-rizatriptan)](https://sec-api.dev/pdufa/meloxicam-rizatriptan) (AXSM)

Calendar months: [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/reboxetine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Reboxetine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/reboxetine

```bibtex
@misc{secapidev_pdufa_reboxetine_20261116,
  title        = {Reboxetine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/reboxetine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_reboxetine_20261116","title":"Reboxetine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/reboxetine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
